Vendor Intelligence Report: Shenzhen Jiechuang Trading

Executive summary

Across 8 Finnrick lab tests, Shenzhen Jiechuang Trading records 6 pass / 2 fail for an overall pass rate of 75%. The entire tested catalog is Tirzepatide, so the headline is narrow: Jiechuang-attributed material has sometimes cleared Finnrick’s public thresholds, but the record does not support blind buying. The pass rate also looks less reassuring under stricter fill-sensitive interpretation, which matters for dose-sensitive buyers.

The sharp signal is unevenness. A 2026 vial labeled Tirzepatide was reported as containing no Tirzepatide, while other lots passed despite substantial quantity swings. For Tirzepatide, the report frames Jiechuang as a verification-only source: exact lot, matching COA, and independent testing before use. For any other peptide, Finnrick has no product-specific basis for confidence.

The identity file is just as important as the chemistry. Shenzhen Jiechuang Trading does not resolve in the public record as a normal retail peptide brand: no verified peptide-sector legal entity under the exact name, no official peptide domain, no public operator, and no public payment rail were confirmed. A Made-in-China company with the same English name sells electronics, not peptides, and is treated as a false-positive collision.

Traceability is weak. The captured lab table shows inconsistent or absent labels and only one formal batch identifier, making recall logic and source authentication difficult when a retail seller claims Jiechuang sourcing. The full report follows that lone batch ID as an open lead and separates confirmed lab facts from unresolved chain-of-custody possibilities.

Inside the full report:

• Full Tirzepatide testing timeline, Finnrick certificates, and captured vendor test table, including the no-active event.
• Per-product pass/fail breakdown and methodology-divergence charts for the single tracked product.
• Corporate identity disambiguation covering Chinese registry gaps, the Made-in-China electronics false positive, and UK trademark name collisions.
• Domain, social, payment, import-record, and affiliate-promotion sweep results.
• Packaging and batch-control analysis, including the lone Batch ID 546853 traceability lead.

Risk assessment

• Tirzepatide product-integrity failure — high: A March 4, 2026 tested vial labeled Tirzepatide was reported as not containing Tirzepatide; root cause is unresolved but buyer risk is direct.
• Tirzepatide lot-consistency risk — high: Finnrick's current record is 8 Tirzepatide tests with 6 pass / 2 fail and 76.61%; captured certificates show major fill variability requiring lot-by-lot testing.
• Traceability and recallability gap — medium: Test captures show inconsistent or unlabeled Tirzepatide packaging and batch identifiers absent on most samples, limiting recall and adverse-event tracking.
• Opaque corporate identity and authenticity-verification risk — medium: No verified peptide-sector legal entity, official domain, or public storefront was identified; unrelated Jiechuang businesses create brand-confusion risk.